MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.

Autor:	Mansouri A; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada., Hachem LD; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada., Mansouri S; MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Nassiri F; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.; MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Laperriere NJ; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Xia D; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada., Lindeman NI; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Chakravarti A; Radiation Oncology, The Ohio State University College of Medicine, Columbus, Ohio, USA., Mehta MP; Department of Radiation Oncology, Miami Cancer Institute, Miami, Florida, USA., Hegi ME; Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland., Stupp R; Malnati Brain Tumor Institute of the Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Aldape KD; Department of Laboratory Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Zadeh G; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.; MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Division of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
Jazyk:	angličtina
Zdroj:	Neuro-oncology [Neuro Oncol] 2019 Feb 14; Vol. 21 (2), pp. 167-178.
DOI:	10.1093/neuonc/noy132
Abstrakt:	Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally poor prognosis. The emergence of molecular biomarkers has had a significant impact on histological typing and diagnosis, as well as predicting patient survival and response to treatment. The methylation status of the O6-methylguanine-DNA methyl-transferase (MGMT) gene promoter is one such molecular biomarker. Despite the strong evidence supporting the role of MGMT methylation status in prognostication, its routine implementation in clinical practice has been challenging. The methods and optimal cutoff definitions for MGMT status determination remain controversial. Variation in detection methods between laboratories presents a major challenge for consensus. Moreover, consideration of other clinical and genetic/epigenetic factors must also be incorporated into treatment decision making. In this review, we distill the available evidence to summarize our position on the optimal use of available assays, and propose strategies for resolving cases with equivocal methylation status and a framework for incorporating this important assay into research and clinical practice. (© The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu